Gufic Biosciences Limited (GUFICBIO.NS)
INR 450.25
(0.18%)
INR 450.25
(0.18%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 10.92 Billion INR | 26.87% |
| 2022 | 8.61 Billion INR | 65.16% |
| 2021 | 5.21 Billion INR | 32.99% |
| 2020 | 3.92 Billion INR | 10.06% |
| 2019 | 3.56 Billion INR | 27.44% |
| 2018 | 2.79 Billion INR | 18.41% |
| 2017 | 2.36 Billion INR | 32.76% |
| 2016 | 1.77 Billion INR | 16.83% |
| 2015 | 1.52 Billion INR | 19.57% |
| 2014 | 1.27 Billion INR | 14.52% |
| 2013 | 1.11 Billion INR | 24.08% |
| 2012 | 895.76 Million INR | 20.84% |
| 2011 | 741.27 Million INR | 22.33% |
| 2010 | 605.97 Million INR | 9.07% |
| 2009 | 555.56 Million INR | 17.33% |
| 2008 | 473.52 Million INR | -3.32% |
| 2007 | 489.8 Million INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q2 | 9.69 Billion INR | 0.0% |
| 2023 FY | 10.92 Billion INR | 26.87% |
| 2023 Q4 | 10.92 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q1 | - INR | -100.0% |
| 2022 Q4 | 8.61 Billion INR | 0.0% |
| 2022 FY | 8.61 Billion INR | 65.16% |
| 2022 Q2 | 6.94 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 5.21 Billion INR | 32.99% |
| 2021 Q2 | 5.12 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 5.21 Billion INR | 0.0% |
| 2020 Q2 | 3.66 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 3.92 Billion INR | 10.06% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 3.92 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 3.56 Billion INR | 27.44% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 3.08 Billion INR | 0.0% |
| 2019 Q4 | 3.56 Billion INR | 0.0% |
| 2018 Q4 | 2.79 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 2.57 Billion INR | 0.0% |
| 2018 FY | 2.79 Billion INR | 18.41% |
| 2018 Q1 | - INR | -100.0% |
| 2017 Q1 | - INR | -100.0% |
| 2017 FY | 2.36 Billion INR | 32.76% |
| 2017 Q4 | 2.36 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 2.28 Billion INR | 0.0% |
| 2016 Q2 | 1.78 Billion INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 FY | 1.77 Billion INR | 16.83% |
| 2016 Q4 | 1.77 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 1.52 Billion INR | 19.57% |
| 2015 Q4 | 1.52 Billion INR | 0.0% |
| 2015 Q2 | 1.5 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 Q2 | 1.31 Billion INR | 0.0% |
| 2014 FY | 1.27 Billion INR | 14.52% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 1.27 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2013 Q2 | 1.06 Billion INR | 0.0% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q4 | 1.11 Billion INR | 0.0% |
| 2013 FY | 1.11 Billion INR | 24.08% |
| 2012 FY | 895.76 Million INR | 20.84% |
| 2012 Q4 | 895.76 Million INR | 0.0% |
| 2012 Q3 | - INR | -100.0% |
| 2012 Q2 | 871.3 Million INR | 0.0% |
| 2011 FY | 741.27 Million INR | 22.33% |
| 2011 Q4 | 741.27 Million INR | 0.0% |
| 2010 FY | 605.97 Million INR | 9.07% |
| 2009 FY | 555.56 Million INR | 17.33% |
| 2008 FY | 473.52 Million INR | -3.32% |
| 2007 FY | 489.8 Million INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Sigachi Industries Limited | 6.94 Billion INR | -57.391% |
| Ind-Swift Limited | 6.54 Billion INR | -66.935% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -42.792% |
| Sakar Healthcare Limited | 3.88 Billion INR | -181.105% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 97.576% |
| Innova Captab Limited | 13.2 Billion INR | 17.287% |
| Divi's Laboratories Limited | 154.7 Billion INR | 92.938% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -1.346% |
| Morepen Laboratories Limited | 12.93 Billion INR | 15.517% |
| Mankind Pharma Limited | 119.63 Billion INR | 90.868% |
| Sequent Scientific Limited | 15.4 Billion INR | 29.073% |
| Wanbury Limited | 3.43 Billion INR | -218.068% |
| Laurus Labs Limited | 83.87 Billion INR | 86.973% |
| Nectar Lifesciences Limited | 21.91 Billion INR | 50.136% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | 61.671% |
| Alembic Limited | 23.28 Billion INR | 53.085% |
| Hikal Limited | 24.87 Billion INR | 56.072% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 83.05% |
| Neuland Laboratories Limited | 18.32 Billion INR | 40.382% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | 72.646% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 92.391% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | 51.321% |
| Themis Medicare Limited | 5.66 Billion INR | -92.887% |
| RPG Life Sciences Limited | 5.12 Billion INR | -113.025% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 96.269% |
| Lupin Limited | 239.97 Billion INR | 95.447% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -197.8% |
| Wockhardt Limited | 76.49 Billion INR | 85.717% |
| Vaishali Pharma Limited | 799.55 Million INR | -1266.434% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | 57.688% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -403.294% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 90.54% |
| FDC Limited | 24.68 Billion INR | 55.733% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 97.181% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -355.109% |
| Eris Lifesciences Limited | 70.48 Billion INR | 84.5% |
| Venus Remedies Limited | 6.26 Billion INR | -74.296% |
| ZIM Laboratories Limited | 4.46 Billion INR | -144.514% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | 9.995% |
| Par Drugs and Chemicals Limited | 1.01 Billion INR | -975.219% |
| Caplin Point Laboratories Limited | 26.97 Billion INR | 59.496% |
| Shilpa Medicare Limited | 30.93 Billion INR | 64.679% |
| Albert David Limited | 4.97 Billion INR | -119.39% |
| Ajanta Pharma Limited | 46.38 Billion INR | 76.446% |
| Hester Biosciences Limited | 6.62 Billion INR | -64.95% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | 51.531% |
| Solara Active Pharma Sciences Limited | 23.46 Billion INR | 53.442% |
| Windlas Biotech Limited | 6.26 Billion INR | -74.47% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -37.537% |
| Aarey Drugs & Pharmaceuticals Limited | 3.04 Billion INR | -258.22% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -227.673% |
| Granules India Limited | 55.2 Billion INR | 80.211% |
| Aarti Drugs Limited | 24.32 Billion INR | 55.083% |
| Bal Pharma Limited | 3.2 Billion INR | -241.005% |
| Alkem Laboratories Limited | 155.74 Billion INR | 92.985% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 98.722% |
| Lincoln Pharmaceuticals Limited | 7 Billion INR | -56.013% |
| Medicamen Biotech Limited | 2.94 Billion INR | -270.954% |
| Unichem Laboratories Limited | 31.69 Billion INR | 65.528% |
| Bafna Pharmaceuticals Limited | 1.47 Billion INR | -639.795% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -2220.474% |
| Valiant Laboratories Limited | 3.42 Billion INR | -218.816% |
| Orchid Pharma Limited | 15.53 Billion INR | 29.689% |
| Medico Remedies Limited | 961.95 Million INR | -1035.754% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | 6.228% |
| Ipca Laboratories Limited | 111.01 Billion INR | 90.158% |
| Brooks Laboratories Limited | 904.45 Million INR | -1107.957% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -169.987% |
| Piramal Enterprises Limited | 826.05 Billion INR | 98.677% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 92.746% |
| NATCO Pharma Limited | 69.06 Billion INR | 84.181% |
| Suven Life Sciences Limited | 2.84 Billion INR | -283.479% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -513.186% |
| Strides Pharma Science Limited | 58.39 Billion INR | 81.291% |
| Indoco Remedies Limited | 21.44 Billion INR | 49.059% |
| Alpa Laboratories Limited | 1.82 Billion INR | -498.254% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -624.167% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -112.128% |